Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.81 |
| ▸ | ENPP1 | P22413 | 3/20 | 0.76 |
| ▸ | P2RY1 | P47900 | 2/20 | 0.76 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.70 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.70 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.70 |
| ▸ | LDHA | P00338 | 1/20 | 0.70 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.70 |
| ▸ | FBP1 | P09467 | 1/20 | 0.70 |
| ▸ | SRC | P12931 | 1/20 | 0.70 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.70 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.70 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.70 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.70 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.70 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.70 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.70 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.70 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20341113 | 1.00 | POLB (0.81) | POLBENPP1P2RY1DNPH1PRKAB2 | |
| SCHEMBL7882477 | 1.00 | POLB (0.81) | POLBENPP1P2RY1DNPH1PRKAB2 | |
| SCHEMBL18785113 | 1.00 | POLB (0.81) | POLBENPP1P2RY1DNPH1PRKAB2 | |
| SCHEMBL11927745 | 1.00 | POLB (0.81) | POLBENPP1P2RY1DNPH1PRKAB2 | |
| SCHEMBL48174 | 1.00 | POLB (0.81) | POLBENPP1P2RY1DNPH1PRKAB2 | |
| SCHEMBL543475 | 1.00 | POLB (0.81) | POLBENPP1P2RY1DNPH1PRKAB2 | |
| Water SCHEMBL112387 | 0.99 | POLB (0.79) | POLBENPP1P2RY1DNPH1PRKAB2 | |
| Triphosphate SCHEMBL27892354 | 0.96 | POLB (0.81) | POLBENPP1P2RY1DNPH1PRKAB2 | |
| SCHEMBL24538794 | 0.93 | POLB (0.77) | POLBENPP1P2RY1DNPH1PRKAB2 | |
| SCHEMBL8742200 | 0.93 | POLB (0.77) | POLBENPP1P2RY1DNPH1PRKAB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230329755-A1 | BONE FLAP FIXATION DEVICE | REVBIO INC (US) | 2023-10-19 | — | — | US | disclosed |
| US-20220401617-A1 | ADHESIVE COMPOSITIONS COMPRISING THERAPEUTICS | REVBIO INC (US) | 2022-12-22 | — | — | US | disclosed |
| US-20170112948-A1 | Inorganic-organic hybrid compound | Karlsruher Institut für Technologie (DE) | 2017-04-27 | — | — | US | disclosed |
| US-20170112948-A1 | Inorganic-organic hybrid compound | Karlsruher Institut für Technologie (DE) | 2017-04-27 | — | — | US | disclosed |
| US-20120108533-A1 | NOVEL PHOSPHATE MODIFIED NUCLEOSIDES USEFUL AS SUBSTRATES FOR POLYMERASES AND AS ANTIVIRAL AGENTS | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170112948-A1 | Inorganic-organic hybrid compound | SLCO4C1, SLCO2A1, SLCO1A2 | POLB 3337/4885ENPP1 2601/4885P2RY1 947/4885 |
| US-20120108533-A1 | NOVEL PHOSPHATE MODIFIED NUCLEOSIDES USEFUL AS SUBSTRATES FOR POLYMERASES AND AS ANTIVIRAL AGENTS | PNP, TYMP, MTAP | POLB 6/4885ENPP1 46/4885P2RY1 519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.